Pasithea Therapeutics (KTTA) Net Income towards Common Stockholders (2021 - 2024)
Historic Net Income towards Common Stockholders for Pasithea Therapeutics (KTTA) over the last 4 years, with Q4 2024 value amounting to -$3.2 million.
- Pasithea Therapeutics' Net Income towards Common Stockholders fell 1870829.24% to -$3.2 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$13.9 million, marking a year-over-year decrease of 296329.1%. This contributed to the annual value of -$13.9 million for FY2024, which is 296329.1% down from last year.
- As of Q4 2024, Pasithea Therapeutics' Net Income towards Common Stockholders stood at -$3.2 million, which was down 1870829.24% from -$3.0 million recorded in Q3 2024.
- Pasithea Therapeutics' 5-year Net Income towards Common Stockholders high stood at $630143.0 for Q4 2021, and its period low was -$3.9 million during Q2 2024.
- Its 4-year average for Net Income towards Common Stockholders is -$1.3 million, with a median of -$549609.0 in 2021.
- In the last 5 years, Pasithea Therapeutics' Net Income towards Common Stockholders skyrocketed by 9841.25% in 2023 and then tumbled by 1870829.24% in 2024.
- Quarter analysis of 4 years shows Pasithea Therapeutics' Net Income towards Common Stockholders stood at $630143.0 in 2021, then tumbled by 268.9% to -$1.1 million in 2022, then surged by 98.41% to -$16895.0 in 2023, then plummeted by 18708.29% to -$3.2 million in 2024.
- Its last three reported values are -$3.2 million in Q4 2024, -$3.0 million for Q3 2024, and -$3.9 million during Q2 2024.